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doi:10.1016/j.jtcvs.2006.07.040bjective: Results are presented from the first completed multicenter trial directed
t gaining approval from the US Food and Drug Administration of endovascular
ersus open surgical repair of descending thoracic aortic aneurysms.
ethods: Between September 1999 and May 2001, 140 patients with descending
horacic aneurysms were enrolled at 17 sites and evaluated for a Gore TAG Thoracic
ndograft. An open surgical control cohort of 94 patients was identified by enrolling
istorical and concurrent subjects. Patients were assessed before treatment, at
reatment, and at hospital discharge and returned for follow-up visits at 1 month, 6
onths, and annually thereafter.
esults: One hundred thirty-seven of 140 patients had successful implantation of the
ndograft. Perioperative mortality in the endograft versus open surgical control
ohort was 2.1% (n  3) versus 11.7% (n  11, P  .001). Thirty-day analysis
evealed a statistically significant lower incidence of the following complications in
he endovascular cohort versus the surgical cohort: spinal cord ischemia (3% vs
4%), respiratory failure (4% vs 20%), and renal insufficiency (1% vs 13%). The
ndovascular group had a higher incidence of peripheral vascular complications
14% vs 4%). The mean lengths of intensive care unit stay (2.6  14.6 vs 5.2  7.2
ays) and hospital stay (7.4  17.7 vs 14.4  12.8 days) were significantly shorter
n the endovascular cohort. At 1 and 2 years’ follow-up, the incidence of endoleaks
as 6% and 9%, respectively. Through 2 years of follow-up, there were 3 reinter-
entions in the endograft cohort and none in the open surgical control cohort.
aplan–Meier analysis revealed no difference in overall mortality at 2 years.
onclusions: In this multicenter study early outcomes with descending aortic endovas-
ular stent grafting were very encouraging when compared with those of a well-matched
urgical cohort. However, at 2 years’ follow-up, there is an incidence of endoleaks and
einterventions associated with endovascular versus open surgical repair. Continued
igilant surveillance of patients treated with an endograft is important.
lthough more than 10 years have passed since the first endovascular
treatment of a descending thoracic aortic aneurysm (DTA), there has been
only one comparative report of open versus endovascular repair.1
The prevalence of thoracic aortic aneurysms has appeared to triple in the 2 most
ecent decades.2,3 Whether this represents an increase in the elderly proportion of
ur population, improved diagnostic capabilities, or an actual increase in incidence
The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 2 369
i
t
4
c
c
n
a
m
7
s
b
A
r
e
a
G
d
g
f
M
B
w
e
U
s
r
p
t
r
a
a
s
l
p
a
t
a
d
F
s
e
a
c
s
d
t
S
O
p
v
w
J
d
e
n
(
s
C
w
T
o
M
Surgery for Acquired Cardiovascular Disease Bavaria et al
3
A
CDs unknown. Thoracic aortic aneurysms are now estimated
o affect 10 of every 100,000 elderly adults, with 30% to
0% of these being DTAs. Although open repair has be-
ome a refined surgical procedure, with extracorporeal cir-
ulation for peripheral organ preservation and multiple tech-
iques for spinal cord protection, it has nevertheless been
ssociated with significant mortality, and the cumulative
orbidity in this aged population frequently exceeds 50% to
0%.4,5 The highly invasive nature of this procedure neces-
itates a prolonged recovery period, with return to well-
eing frequently delayed 4 to 6 months postoperatively.
dditionally, high-risk patients previously denied surgical
epair might become surgical candidates if a less-invasive
ndovascular option were possible. For the above reasons,
n endovascular repair is highly attractive.
This report documents the results of the phase II W. L.
ore Tag Multi-Center Trial comparing the results of en-
ovascular repair with those of an open surgical control
roup. The results of this study comprise the data presented
or US Food and Drug Administration panel review.
aterials and Methods
etween September 1999 and May 2001, 140 patients with DTA
ho met strict inclusion and exclusion criteria (Table 1) were
nrolled in a phase II study at 17 sites (Appendix A) across the
nited States and treated with a Gore TAG Endograft. An open
urgical control cohort of 94 patients was identified by screening
ecent surgical cases for eligibility, beginning with the most recent
rocedure and working sequentially backward. Patients receiving
he endograft were also required to be candidates for open surgical
epair. DTAs deemed suitable for repair included all fusiform
neurysms greater than twice the diameter of the normal adjacent
orta or any saccular aneurysm of sufficient severity to warrant
urgical repair. All patients were required to have at least a 2-cm
ength of nonaneurysmal aorta distal to the left carotid artery and
roximal to the celiac axis. Specifically excluded were mycotic
neurysms, unstable patients with rupture, acute or chronic dissec-
ions, and all patients with a connective tissue disorder.
Endograft diameters ranged from 26 to 40 mm, allowing use in
ortas 23 to 37 mm in diameter, with a 7% to 18% oversizing of
iameter determined from the computed tomographic (CT) scan.
ollow-up visits including plain radiographs and CT scans were
cheduled at 1, 6, and 12 months and annually thereafter.
All adverse events were reported by individual sites. These
vents were then verified by independent study monitors. Finally,
Abbreviations and Acronyms
AAA abdominal aortic aneurysm
ASA  American Society of Anesthesiologists
CT  computed tomography
CVA cerebrovascular accident
DTA descending thoracic aortic aneurysmclinical events committee consisting of 4 endovascular and c
70 The Journal of Thoracic and Cardiovascular Surgery ● Febrardiothoracic physicians reviewed selected adverse events to en-
ure consistent adverse event classification. This report includes
ata collected through the 24-month follow-up visit. Follow-up
hrough 5 years continues.
urgical Treatment
pen surgical repair was accomplished by means of the routine in
lace at each member institution. The use of spinal drainage was
ariable. The majority (82%) of the open surgical control group
as composed of subjects with procedure dates ranging from
anuary 1998 through May 2001. The remaining had a procedure
ate earlier than 1998.
Patients in the endograft group were treated with the Gore TAG
ndoprosthesis, a flexible polytetrafluoroethylene graft with a niti-
ol exoskeleton. The device is inserted through a 20F, 22F, or 24F
OD) sheath, depending on device size. Iliac and femoral vessel
ize and degree of calcification were assessed preoperatively on
T scan to allow for smooth introduction of the device. Procedures
ere performed in surgical or radiology suites with fluoroscopic
able 1. Inclusion and exclusion criteria for endograft and
pen surgical cohorts
Inclusion criteria
● Fusiform descending thoracic aortic aneurysm at least
twice the size of the normal adjacent aorta or saccular
aneurysm
● Life expectancy 2 y
● Surgical candidate
● Male or infertile female 21 years old
Specific to TAG device cohort
● Inner aortic diameter of 23-37 mm adjacent to aneurysm
● Lack of significant thrombus or calcification in landing
zones
● Minimum 2 cm of normal thoracic aorta proximal and
distal to aneurysm
● Aortic taper of no more than 4 mm or ability to treat with
more than one graft
Specific to open surgical cohort
● Descending aorta must be clampable distal to the left
carotid artery, and distal anastomosis must be performed
proximal to the celiac axis.
Exclusion criteria
● Mycotic aneurysm
● Hemodynamically unstable ruptured aneurysm
● Major operation (other than planned subclavian to carotid
transposition or bypass) within 30 d
● MI or CVA within 6 wk
● Creatinine 2.0 mg/dL
● Connective tissue disorder
● Acute or chronic aortic dissection
● Planned occlusion of carotid or celiac arteries
● Documented drug abuse within 6 mo
● Participation in another investigational device or drug
study within 1 y
I, Myocardial infarction; CVA, cerebrovascular accident.ontrol, usually after achievement of general anesthesia.
uary 2007
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A
CDIn June 2001, the sponsor received reports of fractures in the
ongitudinal support spine. Based on this, the device was volun-
arily withdrawn from the market in November 2001. Of the 19
eported fractures, only 1 required further intervention. The device
as modified and subsequently tested in a confirmatory study
etween January and June 2004.
tatistical Methods
elected baseline characteristics are compared between the en-
ograft and surgical control cohorts. Continuous variables are
ummarized by using means, standard deviations, and percentiles
eg, medians). Comparison of continuous variables between
roups uses 2-sample t tests. Where normality does not hold, a
ilcoxon rank sum test was used. Categoric variables are sum-
arized by using counts and percentages. Between-group compar-
sons for these variables use the Fisher exact test. Survival analyses
se the Kaplan–Meier method. All tests use a 5% 2-tailed type I
rror rate. No statistical adjustment for multiple testing has been
ade, and P values are considered exploratory. Because of the
imits of data collection in the open surgical control group, a large
ercentage of the aortic morphology characteristics are missing.
or these variables, the distributions are presented, but no tests of
ignificance are indicated.
esults
atient Characteristics
ne hundred forty patients satisfied all inclusion and exclu-
ion criteria (Table 1) between September 1999 and May
001 and were enrolled to receive the TAG thoracic endo-
rosthesis at 17 centers (endograft group). At the same
enters, the open surgical control cohort enrolled 94
atients.
Subject demographics, previous medical history, and
retreatment aortic morphology are listed in (Tables E1 and
2). There was no significant difference in age, sex, body
ass index, aneurysm size or aneurysm length, previous
oronary artery disease, congestive heart failure, stroke,
eripheral arterial disease, or American Society of Anesthe-
iologists class in the endograft group versus the open
urgical control cohort. There was a higher incidence of
ymptomatic aneurysms (38% vs 21%, P  .007) in the
urgical control group. The aortic diameter immediately
roximal (30.8  4.1 vs 33.9  8.3 mm) and distal (29.8 
.7 vs 33.6  7.1 mm) to the aneurysm was larger in the
urgical control group.
istorical Versus Concurrent Open Surgical
ontrol Subjects
f the 94 patients enrolled in the open surgical control
ohort, 44 were concurrent control subjects and 50 were
istorically and retrospectively acquired by selecting the
ost recent surgical patients in reverse chronologic order.
ppendices E1 through E3 list a comparison of the concur-
ent versus historical control subjects. The only significant
ifference between the 2 groups was that the concurrent a
The Journal of Thoracicohort were older than the historical cohort (mean age, 71
.3 vs 65.7  10.3 years; P  .01).
arly Outcome
Procedural data. One hundred thirty-seven of the 140
atients scheduled to receive the endograft had successful
eployment of the device. Three patients could not get the
evice because of ileofemoral access limitations. During the
nitial procedure, 234 devices were implanted in the 137
ubjects of the endograft cohort: 61 (45%) patients received
device, 60 (44%) patients received 2 devices, 11 (8%)
atients received 3 devices, and 5 (4%) patients received 4
evices. The most common diameter size of graft implanted
as 34 mm (44%). Grafts larger than 34 mm comprised
5% of the population, and grafts smaller than 34 mm made
p only 21%. Fifteen percent of patients (n  21) had a
onduit constructed to insert the device. Of these, 62% had
liac conduits, 14% had infrarenal aortic conduits, 14% had
emoral conduits, and 10% were not documented. One
atient had an external iliac rupture requiring placement of
all stents. The left subclavian artery was covered in 28
20%) cases. All patients had a left carotid to subclavian
ypass before the subclavian artery was covered. There
ere no patients who had preparatory carotid-subclavian
ypass and then failed to undergo endografting.
Patients in the open surgical control cohort underwent
eft thoracotomy and aneurysm resection with interposition
raft placement. Seventy-eight percent of aneurysms were
epaired with extracorporeal circulatory support. Spinal
rainage was variable as per the protocol at each member
nstitution.
Perioperative mortality. Operative mortality defined as
eath within 30 days of the procedure or on the same
ospital admission was 2.1% (n 3) in the endograft group
ersus 11.7% (n  11) in the open surgical control cohort
P  .004).
ENDOGRAFT COHORT. One early death was due to a post-
perative stroke, and another was due to a cardiac event on
ostoperative day 15. The third death occurred nearly 7
onths after the procedure from septic complications after
long, complicated in-hospital course after respiratory ar-
est. At autopsy, this patient had an aortoesophageal fistula.
OPEN SURGICAL CONTROL COHORT. The causes of death among
he 11 perioperative mortalities in the open surgical cohort
ere respiratory failure (n  6), cerebrovascular accident
CVA; n  3), cardiac arrest (n  1), and aortoesophageal
stula (n  1).
Spinal cord ischemia. The total spinal cord ischemia
ncidence was 2.9% (4/140) in the endograft cohort versus
3.8% (13/94) in the open surgical control group (P 
003). In the endograft cohort 3 patients had paraplegia, and
had paraparesis. Of the 4 patients, 2 were fully recovered,nd 2 had residual weakness. Three of the 4 cases of spinal
and Cardiovascular Surgery ● Volume 133, Number 2 371
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A
CDschemia were diagnosed soon after surgical intervention,
nd 1 was clearly related to ileofemoral bleeding and post-
rocedural hypotension. Two of 4 patients with spinal cord
schemia had previous abdominal aortic aneurysm (AAAs)
reated with aortobifemoral bypass. Forty-two (30%) pa-
ients in the endograft group had previous infrarenal aortic
eplacement, resulting in a 4.8% rate of spinal cord events in
he AAA and endograft subgroup. Paraplegia in patients
ithout previous abdominal aortic replacement was 2%
P  .36, not significant). Three of 4 patients with spinal
schemia had multiple devices placed for a full left subcla-
ian to celiac DTA pavement.
In the open surgical control cohort, of the 13 cases of
pinal ischemia, 8 were paraplegia, and 5 were paraparesis.
ix of the 8 cases of paraplegia resulted in death.
CVAs. CVA was defined as a new neurologic deficit
lasting 24 hours), as determined by CT/magnetic reso-
ance imaging, clinical examination, or both. The incidence
f CVA was similar in the endograft and open surgical
ontrol cohorts (3.6% [n  5] vs 4.3% [n  4], P  .58).
our of the 5 patients with a stroke in the endograft group
ad coverage of the left subclavian artery with the endograft
or a proximal aneurysm and a carotid-subclavian bypass.
f 28 patients undergoing subclavian coverage, 4 (14%)
ad a CVA compared with 1% of patients in whom the graft
erminated distal to the subclavian artery (P  .001).
Other perioperative complications. For other perioper-
tive complications, see Table 2. The endovascular cohort
ad a lower incidence of respiratory failure and renal failure
nd a higher incidence of peripheral vascular complications.
he mean length of intensive care unit stay (2.6  14.6 vs
.2  7.2 days, P  .001) and total length of hospital stay
7.4  17.7 vs 14.4  12.8 days, P  .001) were signifi-
able 2. Early postoperative outcomes
ortality: 30 d or in hospital
espiratory failure*
ostoperative MI
enal failure†
ound infection/dehiscence
I complication (ileus, bowel ischemia, or bowel obstruction)
eripheral vascular complications‡
eurologic complications
CVA
Paraplegia/paraparesis
ean ICU length of stay (d)
ean length of hospital stay (d)
I, Myocardial infarction; GI, gastrointestinal; CVA, cerebrovascular accid
ostoperatively or need for reintubation. †Thirty percent or greater increa
rauma.antly shorter in the endovascular cohort. t
72 The Journal of Thoracic and Cardiovascular Surgery ● Febrollow-up
he mean duration of follow-up was 25.8 months (range,
.13-53.5 months) in the endograft cohort and 24.9 months
range, 0.48-66.3 months) in the open surgical control co-
ort. Through 2 years, follow-up was complete in 86% and
7%, respectively, of the endograft and open surgical
ontrol cohorts. The remaining patients either withdrew,
ere lost to follow-up, or missed the 24-month follow-up
ppointment.
Overall survival. Kaplan–Meier analysis reveals an es-
imated 2-year survival of 78% and 76% (P  .48) in the
ndograft group and the open surgical control cohort, re-
pectively (Figure 1).
Endoleaks. At the 30-day follow-up visit, 11% (12/110)
f patients had an endoleak documented. At 1 year of
ollow-up, there were no new endoleaks that had not been
ocumented at 30 days, and there were 6 ongoing en-
oleaks, for an incidence at 1 year of 6% (6/103). At the
-year follow-up visit, there were 2 new endoleaks present
nd 5 ongoing endoleaks, for a 2-year incidence of 9%
7/80). Of the diagnosed endoleaks, 60% were type I, 12%
ere type II, 12% were type III, and 16% were of an
ndeterminate cause.
Aneurysm regression. There were no cases of aneurysm
upture in either cohort. At 2 years’ follow-up, 45% (30/67)
f the endovascular patients had a decrease in aneurysm size
f 5 mm or greater, 42% (28/67) had no change (5 mm),
nd 13% (9/67) had an increase in aneurysm size of 5 mm
r greater.
Stent migration and fracture. There was 1 case of stent
igration diagnosed by 2 years’ follow-up, with no clinical
equelae. Stent fractures were identified in 19 (14%) pa-
Endovascular group Open surgical group P value
2.1% (n  3) 11.7% (n  11) .004
4% 20% .001
0% 1% .40
1% 13% .01
4% 11% .07
2% 6% .16
14% 4% .015
4% (n  5) 4% (n  4) 1.00
3% (n  4) 14% (n  13) .003
2.6 14.6 5.2 7.2 .001
7.4 17.7 14.4 12.8 .001
CU, intensive care unit. *Mechanical ventilation for longer than 24 hours
baseline creatinine level. ‡Includes embolism, thrombosis, and vascularent; I
se inients through 2 years after treatment. Only one fracture was
uary 2007
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A
CDssociated with a clinical sequela, an endoleak that was
uccessfully treated with an additional endograft.
Aortic reoperation. There were 3 reinterventions in the
ndograft group through 2 years after treatment. Two of the
reinterventions involved a repeat endovascular procedure
ith no operative mortality. One patient in the endovascular
roup was operated on with an open surgical technique 73
ays after the initial procedure, when he presented with
ecurrent infections and positive blood cultures, and a pre-
umptive diagnosis of an infected stent graft was made.
ntraoperatively, the patient was found to have an aortoe-
ophageal fistula that was treated with graft removal and
xtra-anatomic bypass. Postoperatively, this patient had
ultisystem organ failure and died.
iscussion
reatment of thoracic aneurysmal disease is a challenging
ntity. Nonoperative survival is dismal.6,7 Although surgical
esection is durable, perioperative mortality and morbidity
re variable. Earlier reports suggest a perioperative mortal-
ty of 12% to 44%, depending on comorbid conditions8,9
nd urgency of operation. More recent literature from expert
igh-volume centers report mortality in the range of 4% to
% and incidence of paraplegia of less than 3% for isolated
TAs.10,11
As “minimally invasive” endovascular treatment has be-
ome technically feasible, initially with homemade first-
eneration grafts and now with commercially available tho-
acic endografts, it is being offered as an attractive treatment
ption to patients. Thoracic aortic endografts have been
sed with early success in small- to moderate-sized, retro-
pective, single-center series.12-17
We previously reported on the initial results of the Gore
AG Endograft.18 The present report includes a more in-
The Journal of Thoracicepth and complete analysis of the initial data and, impor-
antly, a comparative analysis with an open surgical control
ohort. To our knowledge, this is the largest comparison of
ndovascular versus open surgical repair of DTA.
Although the open surgical control cohort in this study
as not randomized, it is robust for several reasons:
1. It is a multicenter control cohort and not a single-
surgeon experience, thus making it more applicable
to results expected across the country.
2. The control group was subject to the same inclusion
and exclusion criteria as the endograft group (apart
from anatomic indications that make endograft repair
technically unfeasible).
3. Forty-seven percent of the control group was concur-
rently enrolled. All demographic data and past med-
ical history were compared between the concurrent
and historical groups to try and ensure that the his-
torical control subjects (53%) were “similar” patients
to the concurrent group. The only variable that was
significantly different was that the concurrent cohort
was older than the historical cohort (mean age, 71 
9.3 vs 65.7  10.3 years; P  .01).
4. The endograft and open surgical control groups were
of similar age and comorbid status. The higher inci-
dence of symptomatic aneurysms (38% vs 21%, P 
.007) in the open surgical control group likely reflects
the fact that endografts were not available in a timely
fashion for these patients. The aortic diameter imme-
diately proximal and distal to the aneurysm was
larger in the open surgical control group. Aortic
diameter greater than 37 mm in a proximal or distal
landing zone was a contraindication to endovascular
Figure 1. Kaplan–Meier survival curves
for the endograft group versus the open
surgical control cohort.intervention because of the limitations of device size.
and Cardiovascular Surgery ● Volume 133, Number 2 373
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A
CDpecific Findings of This Study
erioperative results were generally improved in the en-
ograft cohort versus the open surgical control cohort. Peri-
perative mortality was lower (2.1% vs 11.7%, P  .004).
engths of intensive care unit and hospital stay were
horter. Postoperative respiratory and renal failure was
ower in the endograft cohort.
The incidence of spinal cord ischemia was 2.9% (n  4)
n the endograft cohort versus 13.8% (n  13, P  .003) in
he open surgical control cohort. Theoretical reasons for
ower spinal cord ischemia rates with an endovascular tech-
ique include no period of aortic crossclamping; fewer
eriods of perioperative hypotension associated with blood
oss or hemodynamic shifts; the ability to tolerate higher
ean arterial pressures because there are no suture lines;
arlier awakening from general anesthesia, which allows
ne to tailor blood pressure management to neurologic
xamination; and slow thrombosis of the aneurysmal sac
ersus acute occlusion of critical vessels in surgical patients.
he 2.9% incidence of spinal ischemia in the endovascular
ohort (and 4.8% rate in patients with a previous AAA) is
onsistent with DTA endograft rates published in the liter-
ture of 3.6% to 6.5%.13-22
Importantly, 2 of the 4 patients with spinal ischemia in
his study made a full recovery. Spinal drainage was not
onsistently implemented in this series. Guidelines19 for the
se of cerebrospinal fluid drainage and somatosensory
voked potentials monitoring during DTA endograft proce-
ures have been recently presented, and the recommenda-
ions for the use of these adjuncts are as follows: (1) patients
ith previous AAA repair and (2) full (subclavian artery to
eliac axis) coverage of the descending aorta (DTA Extent
23).
The 13.8% incidence of spinal ischemia in the open
urgical control cohort is higher than the recent best single-
enter published results of approximately 3%.9,10 This
tudy’s higher rate might be due to several factors:
1. The surgeons performing the open procedures had
various surgical backgrounds.
2. It is a multicenter trial, with variable volume of
thoracic aortic surgery performed in each center.
3. This study excluded patients with aneurysmal dilata-
tion of type B dissections, who are thought to have a
reduced paraplegia rate in comparison with those
with atherosclerotic aneurysms.24
4. There was a variable use of spinal cord protection
techniques, as per surgeon preference.
For the above listed reasons, we believe this higher
ncidence of 13.8% probably better reflects the expected
ncidence throughout the country for all comers.
The incidence of CVA during the first 30 days was
imilar in both cohorts (3.6% for the endograft group vs
.3% for the open repair group). However, strokes in the o
74 The Journal of Thoracic and Cardiovascular Surgery ● Febrndovascular group clustered around those patients who
nderwent coverage of the left subclavian artery. This
esult might reflect a greater proximal atherosclerotic
urden at the aortic arch and brachiocephalic vessels in
atients who require coverage of the subclavian artery.
atients who require endografting at the level of the arch
ight need different adjunctive operative strategies in the
uture to decrease the incidence of CVA in this group.
ollow-up
pen surgical repair is known to be a durable and long-
asting operation with a very low incidence of reoperation,
lthough the actual incidence of reoperation is unknown.
auses of reoperation with open repair include graft infec-
ion, pseudoaneurysm formation at suture lines, ongoing
ortic aneurysmal disease, intercostal patch aneurysms, and
he dreaded complication of aortic-enteric fistulas. The du-
ability and long-term complication rate of thoracic en-
ografts are yet to be determined. Recent publications have
autioned that late aortic complications do develop with
horacic endografts.25,26 What is not clear is the acceptable
requency of reintervention with endografting. Reinterven-
ions in the endograft group might be for reasons similar to
hose for open surgical repair or a new set of complications.
n this study there were no reinterventions required in the
pen surgical group and 3 reinterventions in the endovas-
ular group through 2 years of follow-up. As our knowledge
f the nuances of endografting increases, along with tech-
ical improvements in graft design and delivery, it will be of
nterest to see whether the late complication rate will
ecrease.
There was no difference in overall survival between the
 cohorts through 2 years of follow-up (Figure 1). There
as one late aneurysm-related death (graft infection requir-
ng conversion to open repair) in the endovascular group,
nd no late aneurysm-related deaths in the open surgical
roup. There were no aortic ruptures in either population.
imitations of the Study
he main limitation of the study is that the groups were not
andomized. In addition, 2-year follow-up was available in
nly 77% of the open surgical control cohort and 86% of the
ndograft cohort. DTAs are a slow-growing and indolent
rocess. Until we have long-term follow-up data, it is dif-
cult to know whether endografting has improved the nat-
ral history of these patients. This study was limited to a
ow-risk group of patients with isolated DTAs, and results
ight not be applicable to other pathologies for which
ndografting can be used.
onclusions
n this study of 140 patients treated with endografts versus 94
pen surgical control patients, we conclude the following:
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A
CD1. Perioperative mortality and morbidity were signifi-
cantly less with an endovascular approach.
2. Spinal cord ischemia was significantly less in the
endograft cohort.
3. The overall stroke rate was similar in both the en-
dograft and open surgical control cohorts.
4. The reintervention rate and continued presence of
complications, such as endoleaks, is higher in the
endograft group. The presence of endoleaks can lead
to future complications, but their significance is still
unclear.
5. There was no survival advantage associated with
either strategy after 2 years of follow-up.
As technology continues to improve and we as surgeons
rogress along the learning curve, the long-term complica-
ions of endografting might or might not be mitigated.
herefore continued vigilant surveillance of patients treated
ith endovascular repair is important.
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iscussion
r Joseph S. Coselli (Houston, Tex). Scott, congratulations on an
utstanding presentation and for bringing this information from a
ulticenter clinical trial to us. I believe that your report will be a
eminal investigation into an evolving technology that stands to
orever alter the way we therapeutically approach descending
horacic aortic pathology. Although I believe that aortic stenting is
ere to stay, we must shun the pressure of industry-driven initia-
ives and pursue good science and good medicine with, of course,
ndustry support. We need to shoulder the responsibility of being
he patient’s primary advocate.
You and the coauthors importantly infer the problems associ-
ted with a nonrandomized multicenter trial. I continue to have
roblems with the control group. Most of the control subjects,
3%, were historically and retrospectively acquired. Not all insti-
utions contributed patients to this cohort. Data on aortic charac-
eristics were unavailable in many of the open reconstruction
ontrol patients. Proximal and distal aortic diameters and aneu-
ysm length, for example, were reported in less than 35% of this
ohort; even aneurysm diameter data were missing in 10%. The
ata support that the open repair group did not end up with more
dvanced disease because they had larger aortic diameters and
ere more likely to be symptomatic.
After endograft repair, 17% of the patients had expansion of
heir aneurysm of greater than 1/2 cm over 2 years. Considering
he need for life-long monitoring after endograft repair, especially
n the setting of a research protocol, incomplete 2-year follow-up
f 14% is concerning. Do you think that 2 years really is enough?
and Cardiovascular Surgery ● Volume 133, Number 2 375
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A
CDThe extent of aorta replaced and the location (ie, proximal or
istal or the entire descending thoracic aorta) are related to mor-
idity, primarily stroke and paraplegia. Were comparisons made
etween these 2 groups accounts for these?
Seventy-eight percent of the open repairs had extracorporeal
upport. Was this need for cardiopulmonary bypass and hypother-
ic circulatory arrest suggestive of extensive disease and associ-
ted with increased morbidity or mortality?
One patient died of an aortoesophageal fistula. What do you
elieve the nature of that particular fistula was, how did it occur,
nd what lessons do you think were learned?
The incidence of paraplegia and paraparesis after endovascular
epair was 5% in patients with prior AAA repair. What was the
ncidence of paraplegia or paraparesis after previous AAA repair
n the open group?
The incidence of stroke in the treatment group was 4%. With
he need to traverse the aortic arch with a stiff wire and, for
roximal aneurysms, even advance the deployment device into the
rch, do you and the authors see a need for transesophageal
chocardiography to evaluate the arch for mobile atherosclerotic
isease before implementation of the device?
Using a 30% increase in baseline creatinine level to define
renal dysfunction” as a cutoff point captures patients with clini-
ally insignificant increases. Therefore what was the incidence of
ostoperative dialysis in the 2 groups?
The study excluded patients with recent myocardial infarction
r recent stroke, renal insufficiency, and respiratory insufficiency,
nd interestingly enough, these are the patients in particular who
ight benefit the most from endovascular repair.
Once again, congratulations.
Dr Mitchell. Thank you, Dr Coselli. I will try and answer as
any of your questions as I can remember.
First, is 2 years enough? Absolutely not. We do not know the
xact hazard function, but I think these complications will be
ngoing, hopefully decreasing with time, but we do not know that.
herefore these patients will require lifelong follow-up.
The question of the control group has been an energized dis-
ussion. It is not the best control group, we admit that, but it is the
nly one that we had, and I think all of us are aware of the
ifficulties in trying to get a very aware public to enroll in a
andomized trial.
I cannot answer about the incidence of paraplegia in the open
nd control group as relates to previous abdominal aneurysm
epairs. p
76 The Journal of Thoracic and Cardiovascular Surgery ● FebrAs relates to cardiopulmonary bypass, that was used primarily
s an adjunct for each individual site in their routine repair of
escending thoracic aneurysms, and, in theory, circulatory arrest
nd hypothermia were not supposed to be used for these patient
opulations because they were supposed to be clampable.
Finally, we do agree that transesophageal echocardiography
s an invaluable adjunct for the anesthetic management of these
atients to look at the arch. There is no question that any
anipulation in the arch does predispose this patient population
o stroke, even as little as a stiff guide wire, and certainly,
aving to put your sheath through the arch increases that risk
ven more.
Dr Coselli. Scott, one quick follow-up. You and your group at
tanford have the longest and probably the largest experience with
his particular technology. Would you just comment on your
houghts regarding connective tissue disease, particularly Marfan’s
yndrome, applying this approach?
Dr Mitchell. I think you noticed that patients with Marfan’s
yndrome were specifically excluded from this, and I would con-
inue to urge that to be an exclusion with the exception of replacing
ome remnant aorta between 2 Dacron segments. Therefore if you
re connecting Dacron to Dacron, I think that would be okay.
therwise, I would be very pessimistic that this would be effec-
ive.
Dr Michael C. Maxwell (Mesa, Ariz). The Achilles’ heel of
ndoluminal grafting is the endoleak, and I noticed you had a 15%
ncidence. I talked to other investigators for this graft in the thoracic
osition, and endoleak, particularly type I, seems to be more common
han it is in the abdominal position. Is that something you have also
oticed, and if so, is it something that can be watched, unlike in the
bdominal position, or does it have to be taken care of when identi-
ed?
Dr Mitchell. No, I think type I endoleaks should be managed
n detection. Type II and III endoleaks perhaps can be followed,
ooking at aneurysmal sac size as a surrogate. But we have been
ery aggressive about trying to eliminate all type I endoleaks.
There was just one question I forgot to answer for Dr Coselli,
hat there were some aneurysm enlargements that were unassoci-
ted with endoleaks. This is the so-called endotension, which did
ccur with the old graft because it was thinner. The new revised
raft has a stouter polytetrafluoroethylene column, and we do not
hink that these transmembrane leaks will occur, and hopefully this
henomenon will go away.
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A
CDppendix A. Subject enrollment by investigative site
ite name Principal investigator
Endovascular (n  140)
Enrolled, n (%)
Surgical control (n  94)
Enrolled, n (%)
Total enrolled
niversity of Pennsylvania Joseph Bavaria, MD 14 (10) 16 (17) 30
CSF-Stanford Health Care R. Scott Mitchell, MD
Steven Kee, MD
18 (13) 9 (10) 27
mory University Elliot Chaikof, MD 15 (11) 10 (11) 25
ashington University Gregorio Sicard, MD 14 (10) 10 (11) 24
niversity of Michigan David Williams, MD 13 (9) 10 (11) 23
niversity of Pittsburgh Michel Makaroun, MD 12 (9) 6 (6) 18
assachusetts General Richard Cambria, MD 11 (8) 6 (6) 17
leveland Clinic Foundation Roy Greenberg, MD 10 (7) 4 (4) 14
t Sinai School of Medicine Larry Hollier, MD 8 (6) 3 (3) 11
niversity of Florida James Caridi, MD 7 (5) 3 (3) 10
ayo Clinic Rochester Kenton Zehr, MD 2 (1) 7 (7) 9
orthwestern University Mark Marasch, MD 6 (4) 2 (2) 8
artford Hospital Micheal Hallisey, MD 2 (1) 4 (4) 6
ohns Hopkins Hospital Lawrence Hoffman, MD 2 (1) 3 (3) 5
aylor College of Medicine Joseph Coselli, MD 4 (3) 0 4
edical University of South Carolina Renan Uflatker, MD 1 (1) 1 (1) 2
ale University John Elefteriades, MD 1 (1) 0 1The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 2 377
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A
CDppendix E1. Historical versus concurrent control subjects: Demographics
ariable Concurrent (n  44) Historical (n  50)
P value, concurrent
vs historical
ex, n (%) 1.00
Female 22 (50) 24 (48)
Male 22 (50) 26 (52)
ge (y)
n 44 50
Mean  SD 71.0 9.3 65.7 10.3 .011
Percentiles (25th, median, 75th) 66.0, 73.0, 77.0 60.0, 68.0, 72.0
Range (min, max) 47.0, 88.0 35.0, 84.0
thnicity, n (%) .69
Asian 1 (2) 1 (2)
Black 5 (11) 4 (8)
White 36 (82) 45 (90)
Hispanic 1 (2) 0 (0)
Other 1 (2) 0 (0)
eight (kg)
n 44 50
Mean  SD 79.5 18.5 76.0 16.7 .33
Percentiles (25th, median, 75th) 64.8, 78.3, 90.6 63.2, 76.1, 86.3
Range (min, max) 53.0, 136.0 44.4, 114.4
eight (cm)
n 44 50
Mean  SD 169.8 11.8 169.2 11.0 .81
Percentiles (25th, median, 75th) 160.5, 169.0, 178.0 160.0, 170.0, 178.0
Range (min, max) 145.0, 196.0 140.0, 188.0
MI (kg/m2)
n 44 50
Mean  SD 27.4 4.9 26.4 5.1 .34
Percentiles (25th, median, 75th) 23.9, 27.1, 29.8 22.5, 25.9, 29.2
Range (min, max) 19.5, 39.6 18.6, 40.2
D, Standard deviation; BMI, body mass index.77.e1 The Journal of Thoracic and Cardiovascular Surgery ● February 2007
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A
CDppendix E2. Historical versus concurrent control subjects: Pretreatment medical history
ariable
Concurrent (n  44),
n (%)
Historical (n  50),
n (%)
P value, concurrent
vs historical
oronary artery disease 15 (34) 19 (38) .83
ardiac arrhythmia 14 (32) 15 (30) 1.00
alvular heart disease 4 (9) 5 (10) 1.00
ongestive heart failure 4 (9) 5 (10) 1.00
troke 3 (7) 6 (12) .49
eripheral arterial occlusive disease (infrainguinal) 5 (11) 5 (10) 1.00
rior vascular intervention 23 (52) 29 (58) .68
hromboembolic event 1 (2) 5 (10) .21
neurysm, symptomatic 16 (36) 20 (40) .83
neurysm of traumatic origin 2 (5) 3 (8) .18
ther concomitant aneurysm(s) 9 (20) 17 (34) .17
OPD 18 (41) 18 (36) .67
istory of smoking (current or past) 37 (84) 40 (80) .79
enal dialysis 0 (0) 0 (0) .79
araplegia 0 (0) 0 (0) .79
rectile dysfunction 5 (23) 0 (0) .033
epatic dysfunction 1 (2) 0 (0) .47
leeding disorder(s) 2 (5) 3 (6) 1.00
ancer 4 (9) 8 (16) .37
YHA classification 1.00
I 10 (43) 12 (48)
II 7 (30) 7 (28)
III 6 (26) 6 (24)
N/A 21 (48) 25 (50)
SA classification .89
I 1 (2) 1 (2)
II 3 (7) 2 (4)
III 24 (55) 27 (54)
IV 16 (36) 20 (40)
ummary of mean SVS risk scores
n 44 50
Mean  SD 0.6  0.4 0.6  0.3 .74
Percentiles (25th, median, 75th) 0.4, 0.5, 0.8 0.4, 0.5, 0.8
Range (min, max) 0, 2 0, 2
OPD, Chronic obstructive pulmonary disease; NYHA, New York Heart Association; ASA, American Association of Anesthesiologists; SVS, Society of
ascular Surgery.The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 2 377.e2
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A
CDppendix E3. Historic versus concurrent control subjects: Pretreatment aortic morphology
ariable Concurrent (n  44) Historical (n  50)
orta diameter (mm)
Immediately proximal to aneurysm
n 14 20
Mean  SD 34.5 11.2 33.5 5.9
Range (min, max) 22.0, 60.0 21.0, 45.0
Immediately distal to aneurysm
n 12 21
Mean  SD 32.4 5.3 34.2  8.0
Range (min, max) 21.0, 42.2 18.0, 55.0
neurysm diameter (mm)
n 41 44
Mean  SD 62.8 18.4 63.7 13.1
Range (min, max) 11.4, 113.0 33.0, 100.0
neurysm length (cm)
n 14 18
Mean  SD 11.0 5.7 10.7  5.5
D, Standard deviation.77.e3 The Journal of Thoracic and Cardiovascular Surgery ● February 2007
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A
CDable E1. Baseline characteristics
ariable
Endovascular TAG device
(n  140), n (%)
Surgical control (n  94),
n (%) P value*
emographics
Mean age (y), mean  SD 70.5 10.4 68.2 10.2 .096
Male sex, n (%) 80 (57) 48 (51) .42
Mean BMI (kg/m2), mean  SD 26.4 4.7 26.9 5.0 .44
edical history
Coronary artery disease 69 (49) 34 (36) .060
Congestive heart failure 13 (9) 9 (10) 1.00
Stroke 14 (10) 9 (10) 1.00
Peripheral arterial occlusive disease (infrainguinal) 22 (16) 10 (11) .33
Prior vascular intervention 63 (45) 52 (55) .14
Aneurysm, symptomatic 30 (21) 36 (38) .007
Other concomitant aneurysm(s) 39 (28) 26 (28) 1.00
COPD 56 (40) 36 (38) .89
History of smoking (current or past) 117 (84) 77 (82) .86
Renal dialysis 2 (1) 0 (0) .52
Paraplegia 1 (1) 0 (0) 1.00
Cancer 27 (19) 12 (13) .21
ote: Denominators are the number of patients with known observations for each specific baseline variable. BMI, Body mass index. *P values are based
n the Fisher exact test for categoric variables and a 2-sample t test for continuous variables.
able E2. Pretreatment aortic morphology
ariable
TAG device
(n  140)
Surgical control
(n  94)
orta diameter (mm)
Immediately proximal
to aneurysm
N 140 134
Mean  SD 30.8  4.1 33.9 8.3
Range (min, max) 22.0, 40.0 21.0, 60.0
Immediately distal to
aneurysm
N 140 33
Mean  SD 29.8  3.7 33.6 7.1
Range (min, max) 20.0, 38.0 18.0, 55.0
neurysm diameter (mm)
N 140 85
Mean  SD 63.7  15.2 63.2 15.8
Range (min, max) 20.0, 110.0 11.4, 113.0
neurysm length (cm)
N 140 32
Mean  SD 10.2  6.2 10.9 5.5
Range (min, max) 1.0, 35.0 2.0, 22.0
roximal length neck
(cm)
N 136 29
Mean  SD 6.3 3.9 5.8 5.6
istal neck length (cm)
N 139 22
Mean  SD 8.0 5.5 7.0 5.2T
V
D
MD, Standard deviation.
The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 2 377.e4
